25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Arbutus Biopharma Corp
Buy, Hold or Sell?

Let's analyze Arbutus Biopharma Corp together

I guess you are interested in Arbutus Biopharma Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arbutus Biopharma Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arbutus Biopharma Corp

I send you an email if I find something interesting about Arbutus Biopharma Corp.

1. Quick Overview

1.1. Quick analysis of Arbutus Biopharma Corp (30 sec.)










1.2. What can you expect buying and holding a share of Arbutus Biopharma Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
37.5%

What is your share worth?

Current worth
$0.56
Expected worth in 1 year
$0.50
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.07
Return On Investment
-1.9%

For what price can you sell your share?

Current Price per Share
$3.46
Expected price per share
$2.635 - $3.68
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arbutus Biopharma Corp (5 min.)




Live pricePrice per Share (EOD)
$3.46
Intrinsic Value Per Share
$-3.78 - $-4.06
Total Value Per Share
$-3.21 - $-3.49

2.2. Growth of Arbutus Biopharma Corp (5 min.)




Is Arbutus Biopharma Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$106.8m$133.6m-$21.1m-18.8%

How much money is Arbutus Biopharma Corp making?

Current yearPrevious yearGrowGrow %
Making money-$19.1m-$18.8m-$282k-1.5%
Net Profit Margin-1,171.6%-349.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Arbutus Biopharma Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#346 / 950

Most Revenue
#455 / 950

Most Profit
#673 / 950

Most Efficient
#729 / 950
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arbutus Biopharma Corp?

Welcome investor! Arbutus Biopharma Corp's management wants to use your money to grow the business. In return you get a share of Arbutus Biopharma Corp.

First you should know what it really means to hold a share of Arbutus Biopharma Corp. And how you can make/lose money.

Speculation

The Price per Share of Arbutus Biopharma Corp is $3.46. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arbutus Biopharma Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arbutus Biopharma Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.56. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arbutus Biopharma Corp.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-3.0%-0.10-2.9%-0.10-2.9%-0.15-4.2%-0.17-4.9%
Usd Book Value Change Per Share-0.08-2.4%-0.02-0.5%-0.03-1.0%0.010.2%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.020.5%0.010.4%
Usd Total Gains Per Share-0.08-2.4%-0.02-0.5%-0.03-1.0%0.020.7%0.010.4%
Usd Price Per Share3.85-3.01-2.42-2.81-4.39-
Price to Earnings Ratio-9.25--7.40--6.24--6.63-2.57-
Price-to-Total Gains Ratio-46.87-12.30--10.49-93.75-11.65-
Price to Book Ratio6.83-5.08-3.42-4.64-4.90-
Price-to-Total Gains Ratio-46.87-12.30--10.49-93.75-11.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.46
Number of shares289
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.020.01
Usd Total Gains Per Share-0.020.02
Gains per Quarter (289 shares)-4.756.99
Gains per Year (289 shares)-18.9827.96
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-19-2921718
20-38-48421446
30-57-67632174
40-76-868328102
50-95-10510435130
60-114-12412543158
70-133-14314650186
80-152-16216757214
90-171-18118864242
100-190-20020971270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%9.067.023.09.1%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%9.011.00.045.0%13.027.00.032.5%33.066.00.033.3%
Dividend per Share0.00.04.00.0%1.00.011.08.3%9.00.011.045.0%15.00.025.037.5%15.00.084.015.2%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%10.010.00.050.0%14.026.00.035.0%34.065.00.034.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arbutus Biopharma Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.082-0.016-80%-0.035-58%0.006-1439%0.002-5564%
Book Value Per Share--0.5640.594-5%0.706-20%0.627-10%1.104-49%
Current Ratio--7.0176.536+7%5.873+19%9.946-29%11.443-39%
Debt To Asset Ratio--0.2390.244-2%0.258-8%0.259-8%0.237+1%
Debt To Equity Ratio--0.3140.323-3%0.350-10%0.353-11%0.318-1%
Dividend Per Share----0%-0%0.018-100%0.012-100%
Eps---0.104-0.101-3%-0.100-4%-0.147+41%-0.171+65%
Free Cash Flow Per Share---0.110-0.093-15%-0.114+4%-0.082-26%-0.082-26%
Free Cash Flow To Equity Per Share---0.099-0.022-78%-0.064-35%0.011-1019%0.002-4211%
Gross Profit Margin--1.0001.014-1%1.0000%1.0030%1.0010%
Intrinsic Value_10Y_max---4.057--------
Intrinsic Value_10Y_min---3.779--------
Intrinsic Value_1Y_max---0.338--------
Intrinsic Value_1Y_min---0.353--------
Intrinsic Value_3Y_max---1.068--------
Intrinsic Value_3Y_min---1.088--------
Intrinsic Value_5Y_max---1.861--------
Intrinsic Value_5Y_min---1.850--------
Market Cap655642320.000-11%729544200.000569423460.000+28%459044370.000+59%531904044.000+37%831467209.500-12%
Net Profit Margin---14.725-11.716-20%-3.493-76%-7.388-50%5.999-345%
Operating Margin----8.6180%-3.5400%-6.4920%-29.1590%
Operating Ratio--17.01213.621+25%4.722+260%10.660+60%18.068-6%
Pb Ratio6.134-11%6.8255.085+34%3.419+100%4.644+47%4.904+39%
Pe Ratio-8.313+10%-9.250-7.404-20%-6.244-33%-6.632-28%2.570-460%
Price Per Share3.460-11%3.8503.005+28%2.423+59%2.807+37%4.388-12%
Price To Free Cash Flow Ratio-7.850+10%-8.735-8.151-7%-5.356-39%-7.237-17%-15.852+81%
Price To Total Gains Ratio-42.126+10%-46.87412.296-481%-10.493-78%93.750-150%11.645-503%
Quick Ratio--11.90910.670+12%10.358+15%14.956-20%16.959-30%
Return On Assets---0.140-0.129-8%-0.105-25%-0.121-14%-0.129-8%
Return On Equity---0.184-0.171-7%-0.143-23%-0.164-11%-0.172-7%
Total Gains Per Share---0.082-0.016-80%-0.035-58%0.024-440%0.014-703%
Usd Book Value--106890000.000112499750.000-5%133699250.000-20%118733950.000-10%209136950.000-49%
Usd Book Value Change Per Share---0.082-0.016-80%-0.035-58%0.006-1439%0.002-5564%
Usd Book Value Per Share--0.5640.594-5%0.706-20%0.627-10%1.104-49%
Usd Dividend Per Share----0%-0%0.018-100%0.012-100%
Usd Eps---0.104-0.101-3%-0.100-4%-0.147+41%-0.171+65%
Usd Free Cash Flow---20879868.000-17686822.408-15%-21694000.000+4%-15484614.482-26%-15444457.241-26%
Usd Free Cash Flow Per Share---0.110-0.093-15%-0.114+4%-0.082-26%-0.082-26%
Usd Free Cash Flow To Equity Per Share---0.099-0.022-78%-0.064-35%0.011-1019%0.002-4211%
Usd Market Cap655642320.000-11%729544200.000569423460.000+28%459044370.000+59%531904044.000+37%831467209.500-12%
Usd Price Per Share3.460-11%3.8503.005+28%2.423+59%2.807+37%4.388-12%
Usd Profit---19717000.000-19175000.000-3%-18893000.000-4%-18214050.000-8%-27157250.000+38%
Usd Revenue--1339000.0001685500.000-21%5560250.000-76%4063850.000-67%3324725.000-60%
Usd Total Gains Per Share---0.082-0.016-80%-0.035-58%0.024-440%0.014-703%
 EOD+3 -5MRQTTM+9 -24YOY+12 -205Y+9 -2610Y+7 -28

3.3 Fundamental Score

Let's check the fundamental score of Arbutus Biopharma Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.313
Price to Book Ratio (EOD)Between0-16.134
Net Profit Margin (MRQ)Greater than0-14.725
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.909
Current Ratio (MRQ)Greater than17.017
Debt to Asset Ratio (MRQ)Less than10.239
Debt to Equity Ratio (MRQ)Less than10.314
Return on Equity (MRQ)Greater than0.15-0.184
Return on Assets (MRQ)Greater than0.05-0.140
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Arbutus Biopharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.221
Ma 20Greater thanMa 503.610
Ma 50Greater thanMa 1003.812
Ma 100Greater thanMa 2003.864
OpenGreater thanClose3.470
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Fundamental data was last updated by Penke on 2024-11-14 08:55:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arbutus Biopharma Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A Net Profit Margin of -1,472.5% means that $-14.73 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arbutus Biopharma Corp:

  • The MRQ is -1,472.5%. The company is making a huge loss. -2
  • The TTM is -1,171.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,472.5%TTM-1,171.6%-300.9%
TTM-1,171.6%YOY-349.3%-822.3%
TTM-1,171.6%5Y-738.8%-432.8%
5Y-738.8%10Y599.9%-1,338.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,472.5%-112.2%-1,360.3%
TTM-1,171.6%-221.4%-950.2%
YOY-349.3%-210.0%-139.3%
5Y-738.8%-342.2%-396.6%
10Y599.9%-464.5%+1,064.4%
4.3.1.2. Return on Assets

Shows how efficient Arbutus Biopharma Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • -14.0% Return on Assets means that Arbutus Biopharma Corp generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arbutus Biopharma Corp:

  • The MRQ is -14.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.0%TTM-12.9%-1.1%
TTM-12.9%YOY-10.5%-2.4%
TTM-12.9%5Y-12.1%-0.9%
5Y-12.1%10Y-12.9%+0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.0%-11.3%-2.7%
TTM-12.9%-11.7%-1.2%
YOY-10.5%-11.3%+0.8%
5Y-12.1%-12.7%+0.6%
10Y-12.9%-14.1%+1.2%
4.3.1.3. Return on Equity

Shows how efficient Arbutus Biopharma Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • -18.4% Return on Equity means Arbutus Biopharma Corp generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arbutus Biopharma Corp:

  • The MRQ is -18.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.4%TTM-17.1%-1.3%
TTM-17.1%YOY-14.3%-2.8%
TTM-17.1%5Y-16.4%-0.7%
5Y-16.4%10Y-17.2%+0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.4%-14.2%-4.2%
TTM-17.1%-15.9%-1.2%
YOY-14.3%-14.3%+0.0%
5Y-16.4%-18.5%+2.1%
10Y-17.2%-19.3%+2.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arbutus Biopharma Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arbutus Biopharma Corp is operating .

  • Measures how much profit Arbutus Biopharma Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arbutus Biopharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-861.8%+861.8%
TTM-861.8%YOY-354.0%-507.8%
TTM-861.8%5Y-649.2%-212.6%
5Y-649.2%10Y-2,915.9%+2,266.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-861.8%-310.7%-551.1%
YOY-354.0%-223.5%-130.5%
5Y-649.2%-387.1%-262.1%
10Y-2,915.9%-498.5%-2,417.4%
4.3.2.2. Operating Ratio

Measures how efficient Arbutus Biopharma Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 17.01 means that the operating costs are $17.01 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 17.012. The company is inefficient in keeping operating costs low. -1
  • The TTM is 13.621. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ17.012TTM13.621+3.391
TTM13.621YOY4.722+8.899
TTM13.6215Y10.660+2.961
5Y10.66010Y18.068-7.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.0122.465+14.547
TTM13.6213.253+10.368
YOY4.7223.298+1.424
5Y10.6604.788+5.872
10Y18.0686.494+11.574
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arbutus Biopharma Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arbutus Biopharma Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.02 means the company has $7.02 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 7.017. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.536. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.017TTM6.536+0.481
TTM6.536YOY5.873+0.662
TTM6.5365Y9.946-3.410
5Y9.94610Y11.443-1.497
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0173.637+3.380
TTM6.5363.890+2.646
YOY5.8734.666+1.207
5Y9.9465.953+3.993
10Y11.4436.277+5.166
4.4.3.2. Quick Ratio

Measures if Arbutus Biopharma Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A Quick Ratio of 11.91 means the company can pay off $11.91 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 11.909. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.670. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.909TTM10.670+1.239
TTM10.670YOY10.358+0.312
TTM10.6705Y14.956-4.286
5Y14.95610Y16.959-2.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.9093.086+8.823
TTM10.6703.451+7.219
YOY10.3584.456+5.902
5Y14.9565.931+9.025
10Y16.9596.436+10.523
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arbutus Biopharma Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arbutus Biopharma Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arbutus Biopharma Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Arbutus Biopharma Corp assets are financed with 23.9% credit (debt) and the remaining percentage (100% - 23.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 0.239. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.244. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.239TTM0.244-0.005
TTM0.244YOY0.258-0.014
TTM0.2445Y0.259-0.015
5Y0.25910Y0.237+0.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2390.350-0.111
TTM0.2440.344-0.100
YOY0.2580.310-0.052
5Y0.2590.365-0.106
10Y0.2370.382-0.145
4.5.4.2. Debt to Equity Ratio

Measures if Arbutus Biopharma Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.4% means that company has $0.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 0.314. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.323. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.314TTM0.323-0.010
TTM0.323YOY0.350-0.026
TTM0.3235Y0.353-0.030
5Y0.35310Y0.318+0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3140.394-0.080
TTM0.3230.432-0.109
YOY0.3500.380-0.030
5Y0.3530.451-0.098
10Y0.3180.490-0.172
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arbutus Biopharma Corp generates.

  • Above 15 is considered overpriced but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A PE ratio of -9.25 means the investor is paying $-9.25 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arbutus Biopharma Corp:

  • The EOD is -8.313. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.250. Based on the earnings, the company is expensive. -2
  • The TTM is -7.404. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.313MRQ-9.250+0.937
MRQ-9.250TTM-7.404-1.846
TTM-7.404YOY-6.244-1.160
TTM-7.4045Y-6.632-0.771
5Y-6.63210Y2.570-9.202
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.313-2.303-6.010
MRQ-9.250-2.403-6.847
TTM-7.404-3.148-4.256
YOY-6.244-3.251-2.993
5Y-6.632-6.084-0.548
10Y2.570-6.764+9.334
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arbutus Biopharma Corp:

  • The EOD is -7.850. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.735. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.151. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.850MRQ-8.735+0.885
MRQ-8.735TTM-8.151-0.584
TTM-8.151YOY-5.356-2.795
TTM-8.1515Y-7.237-0.914
5Y-7.23710Y-15.852+8.615
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.850-3.042-4.808
MRQ-8.735-3.234-5.501
TTM-8.151-3.719-4.432
YOY-5.356-4.557-0.799
5Y-7.237-8.332+1.095
10Y-15.852-9.276-6.576
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arbutus Biopharma Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.83 means the investor is paying $6.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arbutus Biopharma Corp:

  • The EOD is 6.134. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.825. Based on the equity, the company is overpriced. -1
  • The TTM is 5.085. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.134MRQ6.825-0.691
MRQ6.825TTM5.085+1.740
TTM5.085YOY3.419+1.666
TTM5.0855Y4.644+0.441
5Y4.64410Y4.904-0.260
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.1341.943+4.191
MRQ6.8252.051+4.774
TTM5.0852.356+2.729
YOY3.4192.454+0.965
5Y4.6443.714+0.930
10Y4.9044.378+0.526
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arbutus Biopharma Corp.

4.8.1. Institutions holding Arbutus Biopharma Corp

Institutions are holding 51.465% of the shares of Arbutus Biopharma Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Morgan Stanley - Brokerage Accounts22.20580.0054192053624259942137.3676
2024-06-30Whitefort Capital Management, LP.6.816324.50871286796758150.0452
2024-06-30BlackRock Inc6.11930.000811552066114744711.0282
2024-06-30Two Seas Capital LP4.54064.304585717517298249.3067
2024-06-30Vanguard Group Inc3.71970.00047022095103418817.2713
2024-06-30Geode Capital Management, LLC1.7550.0009331315835427111.9731
2024-06-30ADAR1 Capital Management LLC1.74241.91883289260121507758.581
2024-06-30Adage Capital Partners Gp LLC1.58910.0172300000000
2024-06-30FourWorld Capital Management LLC1.57465.50042972527-28000-0.9332
2024-06-30State Street Corp1.55440.0004293448132259112.3509
2024-06-30BlackBarn Capital Partners LP1.0970.5688207090000
2024-06-30Hudson Bay Capital Management LP0.89260.02451685000-1835382-52.1359
2024-06-30Rubric Capital Management LP0.89050.1362168109016810900
2024-06-30Advisor Group Holdings, Inc.0.72560.01136983923000.1682
2024-06-30Citigroup Inc0.60460.00231141313914425403.0292
2024-06-30Northern Trust Corp0.55690.00061051325-5279-0.4996
2024-06-30Woodline Partners LP0.49080.0273926534-3144125-77.2387
2024-06-30Corbin Capital Partners LP0.4524.245585330400
2024-06-30Saba Capital Management, LP0.34510.033565142727796774.4302
2024-06-30BOOTHBAY FUND MANAGEMENT, LLC0.32430.044861227700
Total 57.996641.3506109486850+26932151+24.6%

4.9.2. Funds holding Arbutus Biopharma Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Total Stock Mkt Idx Inv2.59610.0011491806400
2024-06-30Morgan Stanley Insight2.2371.1024237726187732679.5342
2024-06-30Morgan Stanley Insight A2.2371.09034237726187732679.5342
2024-10-31iShares Russell 2000 ETF1.97670.02123744715-8414-0.2242
2024-06-30Morgan Stanley Inception1.27982.290424244761684775227.7643
2024-06-30Morgan Stanley Inst Inception I1.27982.28524244761693851231.8359
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr1.24610.00832360662403751.7401
2024-06-30MS INVF Global Insight Z1.11551.1609211311000
2024-08-31Fidelity Small Cap Index0.7550.02031430329-35129-2.3971
2024-09-30EQ/Morgan Stanley Small Cap Growth K0.73851.3887139895413760.0985
2024-10-31SPDR® S&P Biotech ETF0.65280.06731236603-17850-1.4229
2024-10-31iShares Russell 2000 Growth ETF0.6410.0393121426500
2024-10-31iShares Biotechnology ETF0.54650.05651035340-6186-0.5939
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.54650.00891035211-32000-2.9985
2024-09-30Fidelity Extended Market Index0.45920.008869818271053.2164
2024-10-31Schwab US Small-Cap ETF™0.37590.015471210200
2024-09-30Vanguard Russell 2000 ETF0.35330.020766937910021917.6082
2024-10-31State St Russell Sm Cap® Indx SL Cl I0.24880.018747129700
2024-09-30Kennedy Micro Cap0.19760.2943374324-5066-1.3353
2024-09-30NT R2000 Index Fund - NL0.18890.02093579305619418.6236
Total 19.6729.918237266507+7253902+19.5%

5.3. Insider Transactions

Insiders are holding 22.221% of the shares of Arbutus Biopharma Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-02-09Michael J McelhaughSELL200005
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets140,441
Total Liabilities33,551
Total Stockholder Equity106,890
 As reported
Total Liabilities 33,551
Total Stockholder Equity+ 106,890
Total Assets = 140,441

Assets

Total Assets140,441
Total Current Assets132,777
Long-term Assets7,664
Total Current Assets
Cash And Cash Equivalents 31,846
Short-term Investments 95,948
Net Receivables 1,608
Other Current Assets 3,375
Total Current Assets  (as reported)132,777
Total Current Assets  (calculated)132,777
+/-0
Long-term Assets
Property Plant Equipment 4,700
Long-term Assets  (as reported)7,664
Long-term Assets  (calculated)4,700
+/- 2,964

Liabilities & Shareholders' Equity

Total Current Liabilities18,923
Long-term Liabilities14,628
Total Stockholder Equity106,890
Total Current Liabilities
Short-term Debt 468
Other Current Liabilities 7,544
Total Current Liabilities  (as reported)18,923
Total Current Liabilities  (calculated)8,012
+/- 10,911
Long-term Liabilities
Long-term Liabilities  (as reported)14,628
Long-term Liabilities  (calculated)0
+/- 14,628
Total Stockholder Equity
Accumulated Other Comprehensive Income -48,090
Other Stockholders Equity 154,980
Total Stockholder Equity (as reported)106,890
Total Stockholder Equity (calculated)106,890
+/-0
Other
Cash and Short Term Investments 127,794
Common Stock Shares Outstanding 188,997
Current Deferred Revenue10,911
Liabilities and Stockholders Equity 140,441
Net Debt -30,400
Net Working Capital 113,854
Short Long Term Debt Total 1,446



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
39,916
36,988
34,568
32,689
29,298
44,756
42,887
67,603
65,897
68,830
60,437
53,271
48,903
44,376
54,715
50,721
56,436
49,575
46,969
41,069
32,869
27,416
20,983
18,422
15,645
7,834
7,991
6,033
25,769
24,955
25,870
24,834
22,211
62,193
52,152
42,342
39,712
41,648
43,452
41,947
37,047
35,365
35,215
21,019
21,019
19,053
14,862
13,704
14,695
11,632
10,292
52,600
50,496
45,909
43,379
71,716
138,522
132,068
125,059
118,178
787,064
773,800
722,631
712,291
703,254
530,861
514,730
275,919
268,140
255,075
239,845
237,161
270,026
277,014
245,418
227,905
209,216
192,570
117,277
105,535
102,614
97,625
131,104
137,080
146,240
135,376
165,596
204,485
236,877
215,836
203,801
195,419
191,224
176,823
158,641
144,401
150,290
160,043
140,441
140,441160,043150,290144,401158,641176,823191,224195,419203,801215,836236,877204,485165,596135,376146,240137,080131,10497,625102,614105,535117,277192,570209,216227,905245,418277,014270,026237,161239,845255,075268,140275,919514,730530,861703,254712,291722,631773,800787,064118,178125,059132,068138,52271,71643,37945,90950,49652,60010,29211,63214,69513,70414,86219,05321,01921,01935,21535,36537,04741,94743,45241,64839,71242,34252,15262,19322,21124,83425,87024,95525,7696,0337,9917,83415,64518,42220,98327,41632,86941,06946,96949,57556,43650,72154,71544,37648,90353,27160,43768,83065,89767,60342,88744,75629,29832,68934,56836,98839,916
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,743
24,481
23,294
20,399
40,129
34,857
27,330
25,002
26,011
26,724
24,790
19,365
18,624
18,523
17,906
17,906
16,273
12,512
11,551
12,733
9,918
8,741
51,248
49,138
44,539
42,011
70,343
137,001
118,164
111,737
116,418
239,769
215,700
200,027
183,882
174,757
168,085
151,812
132,564
120,268
105,922
90,813
129,366
175,186
157,769
144,025
129,229
112,486
99,583
94,341
93,828
88,333
85,536
121,242
127,704
137,341
83,466
126,536
160,661
172,698
157,791
141,136
151,139
152,854
158,800
141,607
132,027
135,872
148,220
132,777
132,777148,220135,872132,027141,607158,800152,854151,139141,136157,791172,698160,661126,53683,466137,341127,704121,24285,53688,33393,82894,34199,583112,486129,229144,025157,769175,186129,36690,813105,922120,268132,564151,812168,085174,757183,882200,027215,700239,769116,418111,737118,164137,00170,34342,01144,53949,13851,2488,7419,91812,73311,55112,51216,27317,90617,90618,52318,62419,36524,79026,72426,01125,00227,33034,85740,12920,39923,29424,48123,74300000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
2,058
0
0
0
25,634
0
0
0
20,525
0
0
0
35,550
0
0
0
24,976
0
0
0
10,440
0
0
0
4,864
23,752
21,080
21,117
21,130
19,399
29,048
26,919
21,543
23,798
11,981
12,707
23,300
18,176
17,254
15,409
12,344
12,344
10,027
8,880
8,995
8,765
6,821
5,723
47,029
43,059
38,717
35,789
68,717
134,357
85,267
78,177
72,187
232,276
207,200
181,089
166,779
144,772
42,970
26,630
23,413
29,851
24,212
15,225
54,292
12,461
10,193
21,933
36,942
83,969
78,872
90,082
31,799
26,416
45,899
96,918
52,251
79,421
30,954
77,883
109,282
81,330
47,320
24,004
30,776
40,574
27,197
17,531
26,285
43,101
62,788
31,846
31,84662,78843,10126,28517,53127,19740,57430,77624,00447,32081,330109,28277,88330,95479,42152,25196,91845,89926,41631,79990,08278,87283,96936,94221,93310,19312,46154,29215,22524,21229,85123,41326,63042,970144,772166,779181,089207,200232,27672,18778,17785,267134,35768,71735,78938,71743,05947,0295,7236,8218,7658,9958,88010,02712,34412,34415,40917,25418,17623,30012,70711,98123,79821,54326,91929,04819,39921,13021,11721,08023,7524,86400010,44000024,97600035,55000020,52500025,6340002,058000
       Short-term Investments 
0
0
0
22,037
0
0
0
21,928
0
0
0
17,686
0
0
0
3,648
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,166
5,386
4,709
0
12,512
12,480
0
0
0
0
0
0
0
0
0
0
0
0
0
27,210
0
0
0
0
31,966
30,580
39,974
39,974
0
15,006
14,525
27,802
122,340
123,052
107,146
80,528
78,797
72,954
72,060
160,079
144,676
120,085
87,675
26,621
16,410
0
59,035
58,475
36,489
21,378
71,017
52,540
47,425
43,520
46,035
84,147
102,879
110,714
116,137
106,154
125,287
116,649
99,718
86,139
79,198
95,948
95,94879,19886,13999,718116,649125,287106,154116,137110,714102,87984,14746,03543,52047,42552,54071,01721,37836,48958,47559,035016,41026,62187,675120,085144,676160,07972,06072,95478,79780,528107,146123,052122,34027,80214,52515,006039,97439,97430,58031,966000027,210000000000000012,48012,51204,7095,3868,166000000000000000003,64800017,68600021,92800022,037000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,167
2,573
1,838
687
2,544
2,213
520
1,153
1,378
1,254
1,273
1,009
1,183
2,704
3,722
3,722
5,011
2,519
1,368
2,776
2,139
2,090
3,459
4,903
4,719
5,110
369
1,972
539
2,284
2,527
6,238
6,300
2,698
1,382
714
732
671
694
8,314
1,330
1,134
870
1,189
1,664
880
1,820
1,214
1,531
2,488
1,204
1,072
1,108
1,075
1,312
1,265
1,298
1,667
899
1,313
1,970
1,835
4,226
6,126
2,614
7,427
2,376
2,739
2,067
1,608
1,6082,0672,7392,3767,4272,6146,1264,2261,8351,9701,3138991,6671,2981,2651,3121,0751,1081,0721,2042,4881,5311,2141,8208801,6641,1898701,1341,3308,3146946717327141,3822,6986,3006,2382,5272,2845391,9723695,1104,7194,9033,4592,0902,1392,7761,3682,5195,0113,7223,7222,7041,1831,0091,2731,2541,3781,1535202,2132,5446871,8382,5731,16700000000000000000000000000000
       Inventory 
0
0
0
209
197
216
0
0
0
0
0
0
0
0
0
0
0
0
239
0
0
0
0
0
0
0
0
0
200
1,370
649
215
197
160
179
143
0
0
108
0
0
0
0
151
151
218
0
0
0
0
0
0
-2,249
-1,959
-17
872
260
192
0
1,192
-340
0
780
1,068
1,341
1,915
1,331
1,183
1,447
1,455
1,372
2,016
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-2,874
-3,462
-2,614
-5,256
0
0
-6,234
0
0-6,23400-5,256-2,614-3,462-2,87400000000000000000002,0161,3721,4551,4471,1831,3311,9151,3411,0687800-3401,1920192260872-17-1,959-2,2490000002181511510000108001431791601972156491,370200000000000239000000000000216197209000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,212
1,389
1,540
1,812
22,063
17,295
15,012
14,710
15,637
16,728
17,157
17,683
16,741
16,693
3,113
3,113
2,780
2,351
2,152
1,962
1,714
1,551
1,352
1,357
1,370
1,368
1,373
1,521
13,904
13,322
1,760
547,295
558,100
522,604
528,409
528,497
362,776
362,918
143,355
147,872
149,153
149,032
107,795
94,840
119,245
101,393
98,676
96,730
92,987
22,936
11,707
14,281
12,089
9,862
9,376
8,899
51,910
39,060
43,824
64,179
58,045
62,665
44,280
38,370
18,023
17,034
12,374
14,418
11,823
7,664
7,66411,82314,41812,37417,03418,02338,37044,28062,66558,04564,17943,82439,06051,9108,8999,3769,86212,08914,28111,70722,93692,98796,73098,676101,393119,24594,840107,795149,032149,153147,872143,355362,918362,776528,497528,409522,604558,100547,2951,76013,32213,9041,5211,3731,3681,3701,3571,3521,5511,7141,9622,1522,3512,7803,1133,11316,69316,74117,68317,15716,72815,63714,71015,01217,29522,0631,8121,5401,3891,21200000000000000000000000000000
       Property Plant Equipment 
2,748
2,564
2,459
2,445
2,386
2,629
2,583
2,790
3,124
3,597
3,688
3,748
3,758
3,996
3,810
4,096
3,969
4,080
4,115
3,430
3,152
1,532
1,131
949
906
687
574
500
748
1,212
1,389
1,540
1,554
2,356
2,262
2,145
2,509
2,586
2,790
2,686
3,126
3,009
2,936
3,113
3,113
2,780
2,351
2,152
1,962
1,714
1,551
1,352
1,357
1,370
1,368
1,373
1,521
1,676
1,613
1,760
1,778
2,000
2,325
3,183
3,242
3,944
4,086
6,945
11,462
12,743
12,622
12,183
11,829
10,681
10,421
10,145
12,748
12,303
11,967
11,414
10,833
10,316
9,753
9,332
8,899
9,004
8,526
8,075
7,671
7,415
7,062
6,814
6,518
6,955
6,535
6,090
5,741
5,296
4,700
4,7005,2965,7416,0906,5356,9556,5186,8147,0627,4157,6718,0758,5269,0048,8999,3329,75310,31610,83311,41411,96712,30312,74810,14510,42110,68111,82912,18312,62212,74311,4626,9454,0863,9443,2423,1832,3252,0001,7781,7601,6131,6761,5211,3731,3681,3701,3571,3521,5511,7141,9622,1522,3512,7803,1133,1132,9363,0093,1262,6862,7902,5862,5092,1452,2622,3561,5541,5401,3891,2127485005746879069491,1311,5323,1523,4304,1154,0803,9694,0963,8103,9963,7583,7483,6883,5973,1242,7902,5832,6292,3862,4452,4592,5642,748
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,823
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
155,865
156,100
156,637
162,514
162,514
162,514
162,514
24,364
24,364
24,364
24,364
24,364
24,364
22,471
22,471
22,471
22,471
22,471
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000022,47122,47122,47122,47122,47124,36424,36424,36424,36424,36424,364162,514162,514162,514162,514156,637156,100155,865000000000000000000000000003,823000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,228
11,709
0
0
0
10,041
10,070
0
0
0
0
0
0
0
0
0
27,446
24,665
22,224
17,675
14,377
10,969
0
3,215
1,600
0
0
0
42,906
30,534
35,688
56,318
50,450
55,436
37,363
31,790
11,057
10,496
6,284
8,677
6,527
0
06,5278,6776,28410,49611,05731,79037,36355,43650,45056,31835,68830,53442,9060001,6003,215010,96914,37717,67522,22424,66527,44600000000010,07010,04100011,70912,228000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
11,669
11,124
9,506
8,459
7,848
7,231
5,884
4,764
7,476
9,530
9,735
7,189
6,953
6,663
6,816
6,594
6,376
0
0
0
0
0
0
0
0
15,885
15,033
12,867
12,200
13,051
13,937
14,471
14,557
13,732
13,757
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
389,652
390,000
353,601
352,642
352,642
196,318
196,318
99,445
99,445
99,445
99,445
58,647
58,647
58,647
43,836
43,836
43,836
43,836
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000043,83643,83643,83643,83658,64758,64758,64799,44599,44599,44599,445196,318196,318352,642352,642353,601390,000389,6520000000000000000013,75713,73214,55714,47113,93713,05112,20012,86715,03315,885000000006,3766,5946,8166,6636,9537,1899,7359,5307,4764,7645,8847,2317,8488,4599,50611,12411,66900000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
258
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,325
341,000
0
0
0
12,601
12,601
12,601
12,601
12,601
12,601
27,446
24,665
22,224
3,081
14,377
2,817
293
233
173
109
44
44
42,906
0
61
190
180
167
103
62
11
3
0
0
0
0
00003116210316718019061042,90644441091732332932,81714,3773,08122,22424,66527,44612,60112,60112,60112,60112,60112,601000341,0002,3250000000000000000000000000000025800000000000000000000000000000000
> Total Liabilities 
2,074
1,904
1,917
2,508
2,533
3,466
4,064
6,117
6,139
6,065
6,530
7,876
6,435
6,188
4,967
7,346
16,773
14,097
14,274
51,558
36,509
40,118
35,986
36,842
37,175
11,305
8,051
5,878
11,973
9,882
7,955
6,464
4,929
7,932
5,513
4,053
4,364
5,068
6,336
6,510
4,628
7,930
9,678
10,288
10,288
10,629
8,212
8,498
9,309
8,092
9,978
11,678
12,628
11,892
13,543
12,522
33,039
26,923
29,563
30,143
193,373
185,300
168,824
164,612
165,177
99,537
98,105
72,914
79,042
79,289
72,454
54,688
37,608
38,942
30,146
27,671
28,007
28,104
33,640
32,791
29,358
32,114
33,759
35,114
32,091
34,547
35,456
35,046
71,032
62,694
58,284
58,567
47,309
42,130
39,304
38,383
35,653
37,589
33,551
33,55137,58935,65338,38339,30442,13047,30958,56758,28462,69471,03235,04635,45634,54732,09135,11433,75932,11429,35832,79133,64028,10428,00727,67130,14638,94237,60854,68872,45479,28979,04272,91498,10599,537165,177164,612168,824185,300193,37330,14329,56326,92333,03912,52213,54311,89212,62811,6789,9788,0929,3098,4988,21210,62910,28810,2889,6787,9304,6286,5106,3365,0684,3644,0535,5137,9324,9296,4647,9559,88211,9735,8788,05111,30537,17536,84235,98640,11836,50951,55814,27414,09716,7737,3464,9676,1886,4357,8766,5306,0656,1396,1174,0643,4662,5332,5081,9171,9042,074
   > Total Current Liabilities 
1,560
1,419
1,461
1,915
1,560
2,702
1,325
2,584
3,183
3,448
3,168
4,803
3,492
3,451
2,629
4,533
5,953
3,950
4,504
10,877
3,146
6,833
1,965
2,201
1,586
11,136
7,935
5,813
8,940
7,688
6,782
6,464
4,929
7,932
5,447
4,053
4,364
5,068
6,336
6,510
4,628
7,930
9,678
8,133
8,133
8,475
6,406
6,842
7,780
6,823
8,934
10,955
12,319
11,892
13,543
12,522
23,039
16,413
19,488
20,206
24,875
10,500
13,831
10,578
11,112
10,084
8,392
10,585
10,871
11,881
8,235
14,627
10,396
11,541
12,668
11,239
8,823
8,799
8,817
7,828
4,031
6,327
7,608
9,541
6,693
8,841
10,113
11,221
32,409
29,824
27,506
32,857
25,154
24,529
22,324
22,487
20,296
22,595
18,923
18,92322,59520,29622,48722,32424,52925,15432,85727,50629,82432,40911,22110,1138,8416,6939,5417,6086,3274,0317,8288,8178,7998,82311,23912,66811,54110,39614,6278,23511,88110,87110,5858,39210,08411,11210,57813,83110,50024,87520,20619,48816,41323,03912,52213,54311,89212,31910,9558,9346,8237,7806,8426,4068,4758,1338,1339,6787,9304,6286,5106,3365,0684,3644,0535,4477,9324,9296,4646,7827,6888,9405,8137,93511,1361,5862,2011,9656,8333,14610,8774,5043,9505,9534,5332,6293,4513,4924,8033,1683,4483,1832,5841,3252,7021,5601,9151,4611,4191,560
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88
103
76
52
31
9
2,934
0
0
0
0
0
0
0
0
0
2,917
2,806
0
1,785
1,729
1,812
2,990
3,251
3,456
3,501
2,463
2,453
2,002
2,515
7,284
6,777
1,507
4,603
6,217
3,718
6,009
5,061
6,695
5,814
4,906
4,112
8,659
6,545
5,267
6,206
0
599
376
329
340
408
364
378
390
432
357
386
383
439
377
360
372
446
397
412
425
502
453
468
46845350242541239744637236037743938338635743239037836440834032937659906,2065,2676,5458,6594,1124,9065,8146,6955,0616,0093,7186,2174,6031,5076,7777,2842,5152,0022,4532,4633,5013,4563,2512,9901,8121,7291,78502,8062,9170000000002,93493152761038800000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,001
12,001
12,001
12,001
12,001
0
0
0
0
599
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000599000012,00112,00112,00112,00112,0010000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
1,483
1,344
1,387
1,845
1,508
2,647
1,272
2,465
2,737
2,936
2,687
4,335
2,996
2,923
2,101
3,729
2,381
1,413
2,001
929
370
295
74
237
240
168
286
314
2,116
1,162
136
312
153
5,197
4,075
509
3,616
3,161
3,487
1,997
3,375
3,006
4,277
3,044
2,716
1,877
789
1,260
1,288
1,178
1,269
806
1,267
1,475
777
1,217
2,141
1,778
3,389
2,044
7,242
2,802
2,898
2,610
3,993
1,744
2,071
3,215
1,614
3,368
2,291
1,987
943
3,208
3,075
3,192
2,344
685
1,400
2,398
519
1,182
852
2,994
355
2,063
1,042
3,174
1,194
12,474
872
3,520
2,455
1,044
2,260
3,223
3,743
2,652
0
02,6523,7433,2232,2601,0442,4553,52087212,4741,1943,1741,0422,0633552,9948521,1825192,3981,4006852,3443,1923,0753,2089431,9872,2913,3681,6143,2152,0711,7443,9932,6102,8982,8027,2422,0443,3891,7782,1411,2177771,4751,2678061,2691,1781,2881,2607891,8772,7163,0444,2773,0063,3751,9973,4873,1613,6165094,0755,1971533121361,1622,116314286168240237742953709292,0011,4132,3813,7292,1012,9232,9964,3352,6872,9362,7372,4651,2722,6471,5081,8451,3871,3441,483
       Other Current Liabilities 
77
75
74
15
0
0
0
0
328
346
330
333
357
389
387
388
2,981
1,820
1,749
9,172
1,646
4,914
1,470
1,542
894
10,498
7,564
5,416
6,741
61
769
1,735
1,368
6,424
4,252
233
3,611
3,167
3,488
3,403
3,361
3,035
4,265
6,151
6,151
610
302
4,092
1,571
917
2,720
4,015
3,454
3,195
4,949
5,379
12,824
6,590
8,707
5,099
5,623
3,600
1,495
883
2,477
1,620
1,245
660
819
983
1,817
1,239
1,188
2,092
2,738
8,047
414
141
86
253
58
150
317
250
198
132
37
26
7,521
12,474
11,396
12,509
7,198
7,761
7,546
7,048
4,504
8,456
7,544
7,5448,4564,5047,0487,5467,7617,19812,50911,39612,4747,521263713219825031715058253861414148,0472,7382,0921,1881,2391,8179838196601,2451,6202,4778831,4953,6005,6235,0998,7076,59012,8245,3794,9493,1953,4544,0152,7209171,5714,0923026106,1516,1514,2653,0353,3613,4033,4883,1673,6112334,2526,4241,3681,735769616,7415,4167,56410,4988941,5421,4704,9141,6469,1721,7491,8202,981388387389357333330346328000015747577
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,194
1,173
0
0
0
65
0
0
0
0
0
0
0
0
2,155
2,155
2,154
1,806
1,656
1,529
1,269
1,044
723
310
0
0
10,000
10,000
10,510
10,075
9,937
168,498
174,800
154,993
154,034
154,065
89,453
89,713
62,329
68,171
67,408
64,219
40,061
27,212
27,401
17,478
16,432
19,184
19,305
24,823
24,963
25,327
25,787
26,151
25,573
25,398
25,706
25,343
23,825
38,623
32,870
30,778
25,710
22,155
17,601
16,980
15,896
15,357
14,994
14,628
14,62814,99415,35715,89616,98017,60122,15525,71030,77832,87038,62323,82525,34325,70625,39825,57326,15125,78725,32724,96324,82319,30519,18416,43217,47827,40127,21240,06164,21967,40868,17162,32989,71389,453154,065154,034154,993174,800168,4989,93710,07510,51010,00010,000003107231,0441,2691,5291,6561,8062,1542,1552,15500000000650001,1732,19400000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,001
12,001
12,001
12,001
12,001
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000012,00112,00112,00112,00112,0010000000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-88
-103
-76
-52
-31
-9
-2,934
0
0
0
0
0
0
0
0
0
-2,917
-2,806
0
-1,785
-1,729
-1,812
-2,990
-3,251
-3,456
-3,501
-2,463
-2,453
-2,002
-2,515
-7,284
-6,777
-1,507
-4,603
-6,217
-3,718
-6,009
-5,061
-6,695
-5,814
-4,906
-4,112
-8,659
-6,545
-5,267
-6,206
0
3,272
3,263
3,143
3,018
2,887
2,867
2,733
2,593
2,477
2,475
2,355
2,231
2,100
2,088
1,955
1,815
1,671
1,646
1,497
1,343
1,181
1,144
-468
-4681,1441,1811,3431,4971,6461,6711,8151,9552,0882,1002,2312,3552,4752,4772,5932,7332,8672,8873,0183,1433,2633,2720-6,206-5,267-6,545-8,659-4,112-4,906-5,814-6,695-5,061-6,009-3,718-6,217-4,603-1,507-6,777-7,284-2,515-2,002-2,453-2,463-3,501-3,456-3,251-2,990-1,812-1,729-1,7850-2,806-2,917000000000-2,934-9-31-52-76-103-8800000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,736
5,136
6,665
7,497
7,741
7,993
8,253
9,065
10,124
10,014
10,211
10,424
9,576
9,769
4,161
3,126
6,523
6,644
24,823
24,963
25,327
25,787
26,151
19,554
25,398
23,231
25,343
16,296
23,038
22,028
20,193
19,711
18,859
17,601
15,483
14,553
14,176
13,850
0
013,85014,17614,55315,48317,60118,85919,71120,19322,02823,03816,29625,34323,23125,39819,55426,15125,78725,32724,96324,8236,6446,5233,1264,1619,7699,57610,42410,21110,01410,1249,0658,2537,9937,7417,4976,6655,1364,736000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
10,510
10,075
9,937
163,762
156,007
148,328
146,537
146,324
81,460
81,460
41,263
46,046
45,393
42,007
17,636
17,636
17,632
13,317
13,306
12,661
12,661
0
0
0
0
0
0
0
0
0
0
15,585
10,842
10,585
0
3,296
0
0
0
0
0
0
0000003,296010,58510,84215,585000000000012,66112,66113,30613,31717,63217,63617,63642,00745,39346,04641,26381,46081,460146,324146,537148,328156,007163,7629,93710,07510,51010,00000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
37,841
35,084
32,651
30,182
26,639
41,222
38,823
61,486
59,758
62,765
53,907
45,395
42,468
38,188
49,748
43,375
39,663
35,479
32,696
0
0
0
0
0
0
0
0
155
13,797
15,073
17,915
18,370
17,282
54,261
46,639
38,289
35,348
36,580
37,116
35,437
32,420
27,435
25,538
10,731
10,731
8,425
6,651
5,206
5,386
3,540
314
40,923
37,867
34,017
29,836
59,193
105,483
105,145
95,496
88,035
593,691
588,500
553,807
547,679
538,077
431,324
416,625
203,005
189,098
175,786
167,391
182,473
232,418
238,072
215,272
200,234
181,209
164,466
83,637
72,744
73,256
65,511
97,345
101,966
114,149
100,829
130,140
169,439
165,845
153,142
145,517
136,852
143,915
134,693
119,337
106,018
114,637
122,454
106,890
106,890122,454114,637106,018119,337134,693143,915136,852145,517153,142165,845169,439130,140100,829114,149101,96697,34565,51173,25672,74483,637164,466181,209200,234215,272238,072232,418182,473167,391175,786189,098203,005416,625431,324538,077547,679553,807588,500593,69188,03595,496105,145105,48359,19329,83634,01737,86740,9233143,5405,3865,2066,6518,42510,73110,73125,53827,43532,42035,43737,11636,58035,34838,28946,63954,26117,28218,37017,91515,07313,7971550000000032,69635,47939,66343,37549,74838,18842,46845,39553,90762,76559,75861,48638,82341,22226,63930,18232,65135,08437,841
   Common Stock
70,186
68,856
67,745
68,558
64,729
72,709
70,049
94,760
94,528
99,680
95,239
96,173
103,237
112,587
131,037
138,086
137,047
135,144
142,808
149,824
149,043
147,073
154,937
154,578
154,274
161,330
161,547
154,591
168,862
184,911
197,016
197,230
190,349
224,671
215,512
188,537
181,929
197,294
214,568
218,087
225,947
215,543
222,998
10,333,000
10,333,000
242,267
222,360
10,333,000
238,749
232,623
240,393
239,483
234,535
227,044
232,410
216,702
283,640
284,790
288,355
290,004
814,441
821,660
828,578
834,240
840,475
861,148
864,375
867,393
870,847
873,841
876,049
876,108
876,288
878,191
878,805
879,405
882,143
884,623
884,623
898,535
911,099
916,066
965,369
985,939
1,013,118
1,017,416
1,065,710
1,286,636
1,298,212
1,298,409
1,307,654
1,318,737
1,339,453
1,344,195
1,346,015
1,349,821
1,377,315
1,403,334
0
01,403,3341,377,3151,349,8211,346,0151,344,1951,339,4531,318,7371,307,6541,298,4091,298,2121,286,6361,065,7101,017,4161,013,118985,939965,369916,066911,099898,535884,623884,623882,143879,405878,805878,191876,288876,108876,049873,841870,847867,393864,375861,148840,475834,240828,578821,660814,441290,004288,355284,790283,640216,702232,410227,044234,535239,483240,393232,623238,74910,333,000222,360242,26710,333,00010,333,000222,998215,543225,947218,087214,568197,294181,929188,537215,512224,671190,349197,230197,016184,911168,862154,591161,547161,330154,274154,578154,937147,073149,043149,824142,808135,144137,047138,086131,037112,587103,23796,17395,23999,68094,52894,76070,04972,70964,72968,55867,74568,85670,186
   Retained Earnings Total Equity00000-1,237,236-1,220,142-1,203,803-1,181,871-1,164,304-1,150,112-1,134,347-1,112,452-1,088,207-1,065,554-1,045,961-1,025,796-1,004,014-986,932-970,093-942,559-857,264-831,187-805,221-784,325-757,285-757,835-738,070-699,631-688,031-669,776-651,149-432,454-412,859-282,859-266,985-261,721-232,739-217,853-205,864-199,696-191,092-185,01100000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income -48,090-48,308-48,371-48,421-48,884-49,468-49,634-50,488-51,004-50,097-49,406-48,335-48,187-48,199-48,168-48,171-48,127-48,099-47,977-48,229-48,217-48,244-48,192-48,170-48,197-48,185-48,185-48,185-49,782-49,782-49,782-49,782-49,782-49,782-49,782-49,782-41,588-28,264-31,487-22,313-19,035-14,208-17,983-15,825-11,882-11,504-11,742-13,000-17,442-16,669-16,766-16,148-15,695-16,554-15,553-15,553000-11,928000-11,578-10,312-10,725-10,60500000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,837
25,655
25,872
26,208
28,590
27,844
28,538
30,206
30,243
32,817
34,486
36,543
37,809
39,758
40,755
42,840
43,769
44,429
45,500
48,084
49,594
53,738
55,385
55,246
56,803
58,300
59,614
60,751
62,133
63,933
64,096
65,485
67,151
69,134
70,738
72,406
74,238
77,202
0
0
0
0
0
0000077,20274,23872,40670,73869,13467,15165,48564,09663,93362,13360,75159,61458,30056,80355,24655,38553,73849,59448,08445,50044,42943,76942,84040,75539,75837,80936,54334,48632,81730,24330,20628,53827,84428,59026,20825,87225,65524,83700000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
202,665
217,540
20,903
220,503
264,535
254,498
224,137
204,954
222,991
242,227
259,238
254,383
246,086
251,515
275,155
-10,057,845
288,825
270,018
-10,058,123
284,761
279,702
49,008
44,684
42,778
41,620
42,798
25,343
24,837
25,655
25,872
26,208
28,590
27,844
28,538
30,206
30,243
32,817
34,486
36,543
37,809
39,758
40,755
42,840
43,769
44,429
45,500
48,084
49,594
53,738
55,385
55,246
56,803
58,300
59,614
60,751
62,133
63,933
64,096
65,485
67,151
69,134
70,738
72,406
74,238
77,202
79,546
81,270
80,220
81,751
154,980
154,98081,75180,22081,27079,54677,20274,23872,40670,73869,13467,15165,48564,09663,93362,13360,75159,61458,30056,80355,24655,38553,73849,59448,08445,50044,42943,76942,84040,75539,75837,80936,54334,48632,81730,24330,20628,53827,84428,59026,20825,87225,65524,83725,34342,79841,62042,77844,68449,008279,702284,761-10,058,123270,018288,825-10,057,845275,155251,515246,086254,383259,238242,227222,991204,954224,137254,498264,535220,50320,903217,540202,66500000000000000000000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.